Lyka Labs Ltd (LYKALABS) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Lyka Labs Ltd on NSE and BSE, with an AI summary of each filing.
Revised intimation of NSE Notice for imposition of FIne
Others (Uncategorized) · 03 Nov 2026, 11:14 pm
Lyka Labs Fined ₹1.62 Lakh by NSE for Delayed FY26 Annual Report Lyka Labs received a notice from the National Stock Exchange of India (NSE) on 30th Oct'26 imposing a fine of ₹1,62,000 plus applicable GST for non-compliance under Regulation 34 of SEBI (LODR) Regulations, 2015, concerning the delayed submission of its Annual Report for FY26. The company confirmed that the Annual Report has since been submitted and the penalty was paid on 2nd Nov'26. Management stated the fine will have no material impact on its financial position, operations, or broader business activities.
Intimation of NSE Notice and imposition of Fine
Others (Uncategorized) · 02 Nov 2026, 6:40 pm
Lyka Labs Fined ₹1.62 Lakh by NSE Over Delayed Annual Report Submission NSE issued a notice to Lyka Labs imposing a fine of ₹1,62,000 plus applicable GST for non-compliance with Regulation 34 of SEBI LODR Regulations, 2015, following the delayed submission of its FY26 Annual Report. The order was received via email on 30th Oct'26. The company confirmed that the report has since been submitted and the penalty will be paid within 15 days. Lyka Labs stated the fine has no material impact on its financial position, operations, or broader business activities.
As per the letter attached
Change in Management · 31 Oct 2026, 12:13 am
Lyka Labs Posts Q2 FY27 Consolidated Net Profit Of ₹127.11 Lakh Lyka Labs reported a turnaround in Q2 ended 30th Sep'26, posting a consolidated net profit of ₹127.11 lakh against a net loss of ₹321.44 lakh in Q2 FY26, though profit declined QoQ from ₹204.66 lakh. Consolidated revenue from operations grew 20.56% YoY to ₹4,419.95 lakh from ₹3,666.05 lakh. Basic EPS stood at ₹0.36 versus negative ₹0.94 YoY. For H1 ended 30th Sep'26, consolidated revenue rose to ₹8,650.89 lakh with net profit of ₹331.77 lakh. The board also approved re-appointing Independent Director Neeraj Golas for three years.
As per the letter attached
Change in Management · 30 Oct 2026, 11:51 pm
Lyka Labs Q2 FY27 Results: Consolidated PAT Swings to ₹127.11 Lakh Lyka Labs posted a consolidated Q2 FY27 revenue from operations of ₹4,419.95 lakh, up 20.56% YoY from ₹3,666.05 lakh in Q2 FY26 and 4.47% QoQ from ₹4,230.94 lakh. Total income reached ₹4,481.75 lakh. Consolidated Net Profit swung to ₹127.11 lakh versus a loss of ₹321.44 lakh in Q2 FY26, though declining 37.89% QoQ from ₹204.66 lakh, with basic EPS at ₹0.36. For H1 FY27, consolidated PAT stood at ₹331.77 lakh. Additionally, the Board approved re-appointing Independent Director Neeraj Golas for a 3-year term.
As per the letter attached
Financial Result · 30 Oct 2026, 11:29 pm
Lyka Labs Reports Strong Turnaround in Q2 FY27 Consolidated Results Lyka Labs reported a consolidated net profit of ₹127.11 lakhs for the quarter ended 30th Sep'26, turning around from a net loss of ₹321.44 lakhs YoY, though declining QoQ from ₹204.66 lakhs. Revenue from operations grew 20.56% YoY to ₹4,419.95 lakhs (up 4.47% QoQ). For H1 ended 30th Sep'26, consolidated revenue surged 24.14% YoY to ₹8,650.89 lakhs, delivering a net profit of ₹331.77 lakhs versus a loss of ₹221.81 lakhs in H1 FY26. Diluted EPS stood at ₹0.36 for the quarter.
As peer the letter attached
Press Release · 30 Oct 2026, 11:09 pm
Lyka Labs Reports Strong Turnaround in Q2FY27 Results Lyka Labs announced its Q2FY27 results on 30th Oct'26, reporting a consolidated net profit of Rs. 127.11 lacs compared to a net loss of Rs. 321.44 lacs in Q2FY26. Consolidated revenue from operations increased 20.56% YoY to Rs. 4,419.95 lacs, driven by a 51.89% YoY surge in export sales to Rs. 1,415.49 lacs. Consolidated EBITDA margin turned positive to 9.37% from -3.95% YoY. For H1FY27, consolidated revenue rose 24.14% YoY to Rs. 8,650.89 lacs, while net profit stood at Rs. 331.77 lacs versus a loss of Rs. 221.81 lacs.
Lyka Labs Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Outcome · 30 Oct 2026, 10:59 pm
Lyka Labs Reports Q2 FY27 Results; Consolidated Profit Swings to Positive Lyka Labs reported consolidated revenue from operations of ₹4,419.95 lakhs for Q2 ended 30th Sep'26, rising 20.56% YoY from ₹3,666.05 lakhs. Net profit reached ₹127.11 lakhs compared to a net loss of ₹321.44 lakhs in the year-ago period, though dropping 37.89% QoQ from ₹204.66 lakhs. Basic EPS stood at ₹0.36. For the half-year ended 30th Sep'26, consolidated revenue surged to ₹8,650.89 lakhs with a net profit of ₹331.77 lakhs. The board approved the reappointment of Independent Director Neeraj Golas for three years.
As per the letter attached
Outcome · 30 Oct 2026, 10:55 pm
Lyka Labs Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh) ■ Revenue: 4,420 (+20.6% YoY | +4.5% QoQ) ■ EBITDA: 352 (Loss to Profit YoY | -22.5% QoQ) ■ EBITDA Margin (%): 8.0 (Loss to Profit YoY | -277 bps QoQ) ■ PAT: 129 (Loss to Profit YoY | -37.7% QoQ) ■ EPS (INR): 0.36 (Loss to Profit YoY | -36.8% QoQ)
LYKA LABS LIMITED has informed the Exchange about Board Meeting to be held on 30-Oct-2026 to consider and approve the Quarterly Unaudited Financial results of the Company for the period ended September 2026 and Other business.
Intimation · 30 Oct 2026, 5:30 am
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 30 Oct 2026, 5:30 am
LYKA LABS LIMITED has informed the Exchange about Board Meeting to be held on 30-Oct-2026 to consider and approve the Quarterly Unaudited Financial results of the Company for the period ended September 2026 and Other business.
Intimation · 30 Oct 2026, 5:30 am
Lyka Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/10/2026 ,inter alia, to consider and approve As per the letter attached
Intimation · 30 Oct 2026, 5:30 am
Lyka Labs Schedules Board Meeting to Approve Q2 Results Lyka Labs Limited has informed stock exchanges that a meeting of its Board of Directors is scheduled for Friday, 30th Oct'26. The board will inter-alia consider and approve the unaudited standalone and consolidated financial results for the second quarter and half year ended 30th Sep'26, alongside the Limited Review Report issued by the statutory auditors.
As per the letter attached
Annual General Meeting · 11 Aug 2026, 11:13 pm
Lyka Labs Passes All Resolutions at 47th AGM with Overwhelming Majority Lyka Labs announced that all five resolutions proposed at its 47th AGM on 10th Aug'26 were passed with the requisite majority. Key resolutions included the adoption of FY26 financial statements, reappointment of a director, ratification of cost auditor remuneration for FY26 and FY27, and approval of material related party transactions with IPCA Laboratories. All ordinary resolutions received over 99.8% of votes in favour. Promoters abstained from voting on the resolution for related party transactions, which still passed with 99.84% approval from public shareholders.
As per the letter attached
Press Release · 11 Aug 2026, 8:36 pm
Lyka Labs Reports Strong Q1 FY27 with Net Profit Up 159% YoY Lyka Labs reported robust Q1 FY27 results, with Consolidated Net Total Income rising 26.95% YoY to Rs. 4,272.79 Lacs. Net Profit surged 159.06% YoY to Rs. 210.03 Lacs. The strong performance was driven by a 68.03% YoY increase in Export Revenue to Rs. 1,483.42 Lacs and a 15.91% YoY growth in Domestic Revenue to Rs. 2,652.11 Lacs. Standalone EBITDA margin improved to 11.86% from 11.74% in Q1 FY26, while consolidated EBITDA margin expanded to 14.16% from 13.07% in the prior year quarter.
As per the letter attached
Annual General Meeting · 10 Aug 2026, 9:17 pm
Lyka Labs AGM Held; Resolutions Passed on Financials and RPTs Lyka Labs Limited held its 47th AGM on 10th Aug'26, attended by 66 members. Key ordinary resolutions included the adoption of audited financial statements for the year ended 31st Mar'26 and the appointment of a director. Special business involved ratifying cost auditor remuneration for FY26 and FY27, and approving material related party transactions with IPCA Laboratories for FY27. The MD & CEO provided a performance review for FY26. Voting was conducted via remote e-voting, with results to be announced in due course.
As per the letter atatched
Press Release · 10 Aug 2026, 6:17 pm
Lyka Labs Reports Strong Q1 FY27 Results Driven by Export and Domestic Growth Lyka Labs reported strong Q1 FY27 results with consolidated Net Total Income rising 26.95% YoY to Rs 4,272.79 Lacs. Standalone Net Profit grew 70.75% YoY to Rs 199.33 Lacs. Top-line growth was driven by a 68.03% surge in exports to Rs 1,483.42 Lacs and a 15.91% increase in domestic sales. The Branded Veterinary segment was a key domestic driver, growing 97.83% YoY. Consolidated EBITDA margin slightly contracted to 11.74% from 13.07% in Q1 FY26. The results were approved on 10 Aug'26.
As per the letter attached
Financial Result · 10 Aug 2026, 5:57 pm
Lyka Labs Q1 FY27 Results; Board Approves Divestment of Subsidiary Lyka Labs reported Q1 FY27 consolidated net profit of ₹204.66 lakhs, up 105.4% YoY from ₹99.62 lakhs. Revenue from operations was ₹4,230.94 lakhs, a 28.1% YoY increase. On a QoQ basis, the company turned to profit from a loss of ₹806.63 lakhs. The Board also approved the divestment of its 100% stake in its non-material subsidiary, Lyka BDR International Limited. This subsidiary contributed 8% of consolidated income in the last financial year. EPS for the quarter stood at ₹0.57.
As per the letter attached
Outcome · 10 Aug 2026, 5:54 pm
Lyka Labs Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Lakh) ■ Revenue: 4,231 (+28.1% YoY | +50.9% QoQ) ■ EBITDA: 455 (+23.4% YoY | Loss to Profit QoQ) ■ EBITDA Margin (%): 10.7 (-41 bps YoY | Loss to Profit QoQ) ■ PAT: 207 (+121.7% YoY | Loss to Profit QoQ) ■ EPS (INR): 0.57 (+128.0% YoY | Loss to Profit QoQ)
Lyka Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026 ,inter alia, to consider and approve As per the letter attached
Intimation · 10 Aug 2026, 5:30 am
Lyka Labs Board Meeting Scheduled for Q1 FY27 Results Lyka Labs Limited will hold a Board of Directors meeting on 10th Aug'26. The agenda includes the consideration and approval of the unaudited standalone and consolidated financial results for the first quarter ending 30th Jun'26. The meeting will also review the Limited Review Report from the company's statutory auditor.
As per the letter attached
Annual General Meeting · 17 Jul 2026, 4:08 pm
Lyka Labs Sets 47th Annual General Meeting for August 10, 2026 Lyka Labs Limited will hold its 47th Annual General Meeting (AGM) on 10th Aug'26 at 12:30 p.m. via video conference. The Annual Report for FY26 has been dispatched electronically. The cut-off date to determine shareholder eligibility for voting is 3rd Aug'26. The remote e-voting window, facilitated by NSDL, will be open from 9:00 a.m. on 6th Aug'26 until 5:00 p.m. on 9th Aug'26. Business will be transacted through electronic voting.
As per the letter attached
Others (Uncategorized) · 17 Jul 2026, 4:02 pm
Lyka Labs Schedules 47th AGM and Releases FY26 Annual Report Lyka Labs has scheduled its 47th Annual General Meeting (AGM) for 10th Aug'26 at 12:30 PM IST, to be held via video conferencing. The company has dispatched a letter providing a weblink to the FY 2025-26 Annual Report to shareholders whose email addresses are not registered. This action complies with Regulation 36(1)(b) of SEBI Listing Regulations. The cut-off date for determining shareholder eligibility for this communication was 10th Jul'26. The Annual Report is now accessible on the company's website.
As per the letter attached
Others (Uncategorized) · 17 Jul 2026, 2:33 pm
As per the letter attached
Annual General Meeting · 17 Jul 2026, 2:26 pm
Lyka Labs seeks shareholder approval for material related party transactions Lyka Labs will hold its 47th Annual General Meeting (AGM) via video conference on 10 Aug’26. Key agenda items include adopting FY26 financial statements and seeking shareholder approval for material related party transactions with promoter IPCA Laboratories. The proposed transactions for FY27, covering the sale/purchase of goods, services, and inter-corporate deposits, are valued at up to ₹75 crore. The company is also seeking ratification for the appointment and remuneration of Cost Auditors for FY26 and FY27.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Kunal Gandhi & PACs
Acquisition/ Disposal of Shares · 30 Jun 2026, 6:10 pm
Lyka Labs Promoter Kunal Gandhi Increases Stake via Open Market Purchase Promoter Kunal Gandhi acquired 14,176 shares (0.04% stake) of Lyka Labs Limited via an open market transaction on 29th Jun'26. Following the acquisition, his individual holding increased from 9.81% to 9.85%. The total holding of the promoter and Persons Acting in Concert (PACs) has now risen to 57,91,851 shares, representing 16.23% of the company's total voting capital, up from 16.19% previously. The company's total equity share capital remains at 3,56,90,000 shares post-transaction.
As per the letter attached
Others (Uncategorized) · 30 Jun 2026, 5:21 pm
Lyka Labs Promoter Kunal Gandhi Increases Stake via Open Market Purchase Promoter Mr. Kunal Gandhi acquired 14,176 equity shares of Lyka Labs Limited through an open market purchase on 29th Jun'26 for a total value of ₹10,28,414.16. Following the transaction, his shareholding increased from 35,00,162 shares (9.81% stake) to 35,14,338 shares (9.85% stake). The company disclosed this under SEBI's insider trading regulations on 30th Jun'26.